echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Endocrine System > NEJM: Golimumab partially restores islet function in young people with new type 1 diabetes

    NEJM: Golimumab partially restores islet function in young people with new type 1 diabetes

    • Last Update: 2020-11-26
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Type I diabetes is an autoimmune β characterized by the gradual loss of function of islet cells.
    Golumab is a human-based monoclonal antibody α against the cause of tumor necrotization, which can be used to treat a variety of autoimmune diseases in adults and children.
    researchers recently examined the effects on cellular function in newly diagnosed young people with type 3 β type 3 diabetes.
    In this Phase II, multi-center, placebo-controlled, double-blind, parallel group trial, children and young people newly diagnosed with type 1 diabetes (age range, 6 to 21 years old) received subsuperective injections of Golimumab or placebo for 52 weeks.
    end points of the study were endogenic insulin production (assessed based on the concentration-time curve area at the C peptide level) and the 52nd week 4-hour mixed dietary tolerance test (4-hour C peptide AAUC) reaction.
    secondary and additional endpoints include insulin use, glycation hemoglobin levels, hypoglycemia events, and changes in the ratio of peri-abdominal insulin to C peptides.
    84 patients in the study, including 56 in the Golumumab group and 28 in the placebo group.
    week 52, there was a significant difference in the average 4-hour C peptide AAUC between the Goliumumab group and the placebo group (0.64 vs. 0.43 pmol/ml).
    insulin use in the Golumumab group was lower than in the placebo group.
    in the Golumumab group, 43 percent of the participants observed partial remission, while only 7 percent in the placebo group.
    there was a significant difference in the risk of hypoglycemia events between the two groups, with 13 participants (23%) in the Golimumab group having hypoglycemia events (23%) and 2 (7%) having hypoglycemia events in the placebo group.
    antibodies against Golumumab were detected in 30 patients, and 29 participants had antibody effectiveness of less than 1:1000, of which 12 were positive for meso-antibodies.
    study, Golimumab therapy can improve endogen insulin production and reduce the use of extrogenic insulin in people with type 1 diabetes.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.